Your browser doesn't support javascript.
loading
Pembrolizumab plus eribulin in hormone-receptor-positive, HER2-negative, locally recurrent or metastatic breast cancer (KELLY): An open-label, multicentre, single-arm, phase Ⅱ trial.
Pérez-García, José M; Llombart-Cussac, Antonio; G Cortés, María; Curigliano, Giuseppe; López-Miranda, Elena; Alonso, José L; Bermejo, Begoña; Calvo, Lourdes; Carañana, Vicente; de la Cruz Sánchez, Susana; M Vázquez, Raúl; Prat, Aleix; R Borrego, Manuel; Sampayo-Cordero, Miguel; Seguí-Palmer, Miguel Á; Soberino, Jesus; Malfettone, Andrea; Schmid, Peter; Cortés, Javier.
Afiliação
  • Pérez-García JM; International Breast Cancer Center (IBCC), Quiron Group, Barcelona, Spain; Medica Scientia Innovation Research (MEDSIR), Ridgewood, NJ, USA; Medica Scientia Innovation Research (MEDSIR), Barcelona, Spain.
  • Llombart-Cussac A; Medica Scientia Innovation Research (MEDSIR), Ridgewood, NJ, USA; Medica Scientia Innovation Research (MEDSIR), Barcelona, Spain; Hospital Arnau de Vilanova Universidad Católica de Valencia "San Vicente Mártir"Valencia, Spain.
  • G Cortés M; Hospital Universitario Ramón y Cajal, Madrid, Spain.
  • Curigliano G; European Institute of Oncology IRCCS, University of Milano, Milan, Italy.
  • López-Miranda E; Medica Scientia Innovation Research (MEDSIR), Ridgewood, NJ, USA; Medica Scientia Innovation Research (MEDSIR), Barcelona, Spain; Hospital Universitario Ramón y Cajal, Madrid, Spain.
  • Alonso JL; Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, Spain.
  • Bermejo B; Hospital Clínico de Valencia, INCLIVA, CIBERONC, Valencia, Spain.
  • Calvo L; Complejo Hospitalario Universitario A Coruña (CHUAC), A Coruña, Spain.
  • Carañana V; Hospital Arnau de Vilanova, Valencia, Spain.
  • de la Cruz Sánchez S; Complejo Hospitalario de Navarra, Pamplona, Spain.
  • M Vázquez R; MD Anderson Cancer Center, Madrid, Spain.
  • Prat A; Department of Medical Oncology, Hospital Clinic of Barcelona, Barcelona, Spain; Translational Genomics and Targeted Therapies Group, IDIBAPS, Barcelona, Spain; Department of Medicine, University of Barcelona, Barcelona, Spain.
  • R Borrego M; Hospital Universitario Virgen del Rocío, Sevilla, Spain.
  • Sampayo-Cordero M; Medica Scientia Innovation Research (MEDSIR), Ridgewood, NJ, USA; Medica Scientia Innovation Research (MEDSIR), Barcelona, Spain.
  • Seguí-Palmer MÁ; Corporació Sanitaria Sanitari Parc Taulí, Sabadell, Spain.
  • Soberino J; IOB, Institute of Oncology, QuironSalud Group, Barcelona, Spain.
  • Malfettone A; Medica Scientia Innovation Research (MEDSIR), Ridgewood, NJ, USA; Medica Scientia Innovation Research (MEDSIR), Barcelona, Spain.
  • Schmid P; Barts ECMC, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom; Barts Hospital NHS Trust, London, United Kingdom.
  • Cortés J; International Breast Cancer Center (IBCC), Quiron Group, Barcelona, Spain; Medica Scientia Innovation Research (MEDSIR), Ridgewood, NJ, USA; Medica Scientia Innovation Research (MEDSIR), Barcelona, Spain; Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain. Electronic address: jacortes@vhio
Eur J Cancer ; 148: 382-394, 2021 05.
Article em En | MEDLINE | ID: mdl-33794440
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Protocolos de Quimioterapia Combinada Antineoplásica / Receptores de Progesterona / Receptores de Estrogênio / Receptor ErbB-2 / Recidiva Local de Neoplasia Tipo de estudo: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Female / Humans / Middle aged Idioma: En Ano de publicação: 2021 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Protocolos de Quimioterapia Combinada Antineoplásica / Receptores de Progesterona / Receptores de Estrogênio / Receptor ErbB-2 / Recidiva Local de Neoplasia Tipo de estudo: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Female / Humans / Middle aged Idioma: En Ano de publicação: 2021 Tipo de documento: Article